GLP-1 drugs: India's regulatory authorities take firm steps to prevent unsupervised use
New Delhi, April 1
The Drug Controller General of India has stepped up regulatory surveillance against unauthorised sale and promotion of type 2 diabetes drugs also known as GLP-1 drugs, the government said on Wednesday.
In recent weeks, 49 businesses were audited and inspected across the country, including online pharmacy warehouses, drug wholesalers, retailers, and weight loss clinics, an official statement said.
These inspections spanned multiple regions across India and focused on identifying violations related to unauthorised sale, improper prescription practices, and misleading marketing.
The government also issued notices to those found breaking the rules. Stricter inspections and surveillance will continue in the coming weeks. Businesses that break the rules will face license cancellation, fines, and legal action, the statement said.
The government also mentioned that only endocrinologists, internal medicine specialists and cardiologists can prescribe them.
It had issued an advisory on March 10, 2026, directing manufacturers to stop misleading advertisements or any promotion that could encourage use without a prescription.
GLP-1 drugs (glucagon‑like peptide‑1 receptor agonists) treat type 2 diabetes and obesity but carry risks ranging from nausea and vomiting to severe complications such as pancreatitis, kidney injury and bowel obstruction.
Due to these side effects, the government urged patients to consult qualified medical specialists and obtain these medications only with a prescription through legitimate, regulated channels.
Multiple variants of GLP-1 drugs have been recently introduced in the Indian market, and concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics.
GLP-1 drugs (glucagon-like peptide-1 receptor agonists) are medications stimulating insulin release and suppressing excess glucagon, to bring blood sugar back under control. GLP-1 triggers the pancreas to release insulin, which moves glucose out of the bloodstream and into cells, where it is used for energy.
The drug slows down the gastric emptying, increasing the feeling of fullness and decreases patients' appetites and thereby leads to their weight loss.
— IANS
Reader Comments
Good move! But the government should also focus on public awareness. Many middle-class families see these as a shortcut for weight loss for weddings and functions. They need to know about pancreatitis and kidney risks. Jaan hai toh jahaan hai.
While I support the crackdown, I hope this doesn't make it excessively difficult for genuine diabetes patients to get their prescriptions filled. Sometimes, over-regulation creates shortages and black markets. The focus should be on the online pharmacies and clinics selling without checks.
As someone who moved to India recently, the casual availability of prescription drugs was shocking. Back home, you simply cannot get these without a specialist's script. This regulatory action brings India in line with global best practices for patient safety.
Finally! My cousin got it from a "wellness clinic" in Delhi without any proper tests. Ended up with severe nausea and had to be hospitalized. These clinics and online platforms operate like candy stores. License cancellation is the only language they understand.
The pressure to look a certain way, especially for women, is huge. These drugs are being exploited because of that. Government action is good, but we also need a societal shift. Health over unrealistic beauty standards, please! 💪
We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.